论文部分内容阅读
目的评价通关胶囊对良性前列腺增生(BPH)患者的增生前列腺细胞外基质(ECM)的影响,并探讨其作用机理。方法选择具备手术指征的BPH病人30例,按就诊顺序随机分为通关胶囊组、非那雄胺组和安慰剂组。服药4周后,行TURP术,留取组织标本。另选正常前列腺标本6例,用免疫组化法结合图像分析系统研究正常组、安慰剂组、通关胶囊组和非那雄胺组前列腺组织纤维连接蛋白(FN)、胶原(CL)、基质金属蛋白酶2(MMP-2)、金属蛋白酶组织抑制因子2(TIMP-2)和模型基质金属蛋白酶1(MT1-MMP)的阳性表达。结果安慰剂组前列腺组织的FN、CL和MT1-MMP的阳性表达较正常组显著增强,差异有统计学意义(P<0.01),MMP-2/TIMP-2差异无统计学意义(P>0.05);通关胶囊组、非那雄胺组与安慰剂组的前列腺组织比较,FN和CL的阳性表达较安慰剂组明显减弱(P<0.01),MT1-MMP和MMP-2/TIMP-2较安慰剂组明显增高(P<0.01)。结论通关胶囊能降低增生前列腺组织ECM成分,避免其沉积,其机理可能与其调节ECM成分及其相关调控因子在前列腺组织中的表达有关。
Objective To evaluate the effect of “Tongguan Capsule” on Proliferative Prostate Extracellular Matrix (ECM) in Patients with Benign Prostatic Hyperplasia (BPH) and to explore its mechanism. Methods Thirty BPH patients with surgical indication were randomly divided into two groups according to the order of treatment: capsule group, finasteride group and placebo group. Taken 4 weeks after TURP surgery, tissue samples were taken. In addition, 6 cases of normal prostate specimens were selected, and immunohistochemistry and image analysis system were used to study the changes of fibronectin (FN), collagen (CL), matrix metalloproteinases (MMPs) in normal group, placebo group, Protease 2 (MMP-2), tissue inhibitor of metalloproteinase 2 (TIMP-2) and the expression of matrix metalloproteinase 1 (MT1-MMP). Results The positive expression of FN, CL and MT1-MMP in prostate tissue in placebo group was significantly higher than that in normal group (P <0.01), and there was no significant difference in MMP-2 / TIMP-2 (P <0.01). Compared with placebo group, the positive expression of FN and CL in finasteride group and finasteride group was significantly lower than that in placebo group (P <0.01). MT1-MMP and MMP-2 / TIMP- Placebo group was significantly higher (P <0.01). Conclusion Tongguan Capsule can reduce the proliferation of prostatic tissue ECM composition, to avoid its deposition, the mechanism may be related to its regulation of ECM components and related regulatory factors in prostate tissue expression.